TLR4/Myd88Signal Factor Experimental Study Of Expression And Significance In Breast Cancer

Objective: To investigate the expression and significance of TLR4/MyD88signalfactor in breast cancer, and elucidate breast cancer tumor growth and invasion of themolecular mechanisms, for the subsequent development of new therapeutic strategiesin breast cancer provide new ideas.Methods: According to the data sheet selected randomly from the hospital fromJanuary2008to September2012which established a database of60cases of breastcancer, adjacent tissues,20cases of breast fibroadenoma,and collected the surgicalresection of10cases of breast cancer in breast cancer patients and10cases of theiradjacent tissues,10cases of breast fibroadenoma in Fujian Medical UniversityAffiliated First Hospital thyroid and breast Surgery department from January2013toJune2013. Use the Immunohistochemical staining SP method to detect TLR4,MyD88protein expression levels in breast cancer,breast fibroadenoma and adjacentnoncancerous tissues, and observe the characteristics and changes of expression inthe organization. RT-PCR was used to detect TLR4, MyD88gene and proteinexpression levels in breast cancer, breast fibroadenoma and adjacent noncanceroustissues.Results:1: Immunohistochemical results1. TLR4in breast cancer, benign breast tumor and adjacent normal tissues rates were63.3%,20.0%and10%,,(P <0.001); MyD88in breast cancer, benign breast tumorand adjacent normal tissues rates were58.3%,20.0%and15%(P=0.003), thedifferences were statistically significant.2. TLR4expression in breast cancer tissue and axillary lymph node metastasis (P=0.006), tumor size (P=0.017), tumor stage (P=0.013) and distant metastasis (p= 0.038) correlation; MyD88expression in tumor size (P=0.009), tumor stage (P=0.030), axillary lymph node metastasis (P=0.006) and distant metastasis (p=0.004)correlation, the differences were statistically significant.3.4-year overall survival (overall survival, OS) rate of positive TLR4proteinexpression in breast cancer patients was18.0%, lower than4-year overall survival rateof negative TLR4protein expression in breast cancer patients was73.2%, thedifference was statistically significant (χ2Log-rank=5.606, P=0.018).4-year overallsurvival rate (OS) of positive MyD88protein expression in breast cancer patients was18.9%, lower than4-year overall survival rate of negative MyD88protein expressionin breast cancer patients was54.3%, the difference was not statistically significant (χ2Log-rank=0.92, P=0.336).4.4-year disease-free survival (disease free survival, DFS) rate of positive TLR4protein expression in breast cancer patients was19.8%, lower than4-year disease-freesurvival rate of negative TLR4protein expression in breast cancer patients was48.8%,the difference was not statistically significant (χ2Log-rank=3.291, P=0.070).4-yearDFS of rate of positive MyD88protein expression in breast cancer patients was11.1%, lower than4-year disease-free survival rate of negative MyD88proteinexpression in breast cancer patients was55.1%, the difference was statisticallysignificant (χ2Log-rank=3.828, P=0.043).2:Real Time PCR resultsTLR4gene expression of breast cancer was (35.39±7.71),higher than TLR4ofbenign breast tumor gene expression (13.36±6.91),(t=6.73, P <0.05),and TLR4gene expression of the adjacent tissues of the mammary gland (1.00±0.51),(t=14.08, P <0.05), MyD88gene expression of breast cancer was (18.23±4.65),higher than the MyD88gene expression of benign breast tumor(4.13±2.12),(t=8.73, P <0.05), and MyD88gene expression in adjacent normal breast tissue (2.97±2.57),(t=9.08, P <0.05), that can be seen, TLR4, MyD88gene expression in breastcancer, compared to benign breast tumor and adjacent normal tissues wassignificantly increased, the differences were statistically significant (P <0.05). Conclusion:1.TLR4and MyD88protein in breast cancer tissues showed high expression, and itsexpression in breast tissue pathological features such as tumor size, tumor stage,axillary lymph node metastasis and distant metastasis were positively correlated.2.Compared to TLR4, MyD88expressed in adjacent normal tissue and benign breasttumor, TLR4, MyD88express in breast cancer was significantly enhanced, and thedifference was statistically significant.